Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer

PURPOSE:To prospectively investigate whether Lipiodol can be used as a potential imaging biomarker of tumor response after conventional transarterial chemoembolization (cTACE) for both primary and secondary liver cancer. MATERIALS AND METHODS: This prospective single-center single-arm clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Miszczuk, Milena A., Chapiro, Julius, Geschwind, Jean-Francois H., Thakur, Vinayak, Nezami, Nariman, Laage-Gaupp, Fabian, Kulon, Michal, van Breugel, Johanna M.M., Fereydooni, Arash, Lin, MingDe, Savic, Lynn Jeanette, Tegel, Bruno, Wahlin, Tamara, Funai, Eliot, Schlachter, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036424/
https://www.ncbi.nlm.nih.gov/pubmed/32092672
http://dx.doi.org/10.1016/j.tranon.2020.01.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036424/
https://www.ncbi.nlm.nih.gov/pubmed/32092672
http://dx.doi.org/10.1016/j.tranon.2020.01.003

Ejemplares similares